RÉSUMÉ
The original version of this article, published on 17 April 2018, unfortunately contained a mistake.
RÉSUMÉ
PURPOSE: To determine the frequency and characteristics of contralateral, non-recalled breast abnormalities following recall at screening mammography. METHODS: We included a series of 130,338 screening mammograms performed between 1 January 2014 and 1 January 2016. During the 1-year follow-up, clinical data were collected for all recalls. Screening outcome was determined for recalled women with or without evaluation of contralateral breast abnormalities. RESULTS: Of 3,995 recalls (recall rate 3.1%), 129 women (3.2%) underwent assessment of a contralateral, non-recalled breast abnormality. Most lesions were detected at clinical mammography and/or breast tomosynthesis (101 women, 78.3%). The biopsy rate was similar for recalled lesions and contralateral, non-recalled lesions, but the positive predictive value of biopsy was higher for recalled lesions (p = 0.01). A comparable proportion of the recalled lesions and contralateral, non-recalled lesions were malignant (p = 0.1). The proportion of ductal carcinoma in situ was similar for both groups, as well as invasive cancer characteristics and type of surgical treatment. CONCLUSIONS: About 3% of recalled women underwent evaluation of contralateral, non-recalled breast lesions. Evaluation of the contralateral breast after recall is important as we found that 15.5% of contralateral, non-recalled lesions were malignant. Contralateral cancers and screen-detected cancers show similar characteristics, stage and surgical treatment. KEY POINTS: ⢠3% of recalled women underwent evaluation of contralateral, non-recalled lesions ⢠One out of seven contralateral, non-recalled lesions was malignant ⢠A contralateral cancer was diagnosed in 0.5% of recalls ⢠Screen-detected cancers and non-recalled, contralateral cancers showed similar histological characteristics ⢠Tumour stage and surgical treatment were similar for both groups.